Goodwin
Arman Oruc
- Deals
- 10
- Latest
- May 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 10 deals
Often works with
- Daniel Karelitz 6 deals together
- Kevin Walsh 5 deals together
- Andrea Akinbola 4 deals together
- Simone Waterbury 4 deals together
- Dan Karelitz 4 deals together
- Gozde Guckaya 4 deals together
- Felipe M. Heiderich 3 deals together
- Wei Xu 3 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| May 2026 | Anagram Therapeutics | – | – | Stake | Legal adviser to Anagram Therapeutics (target) | Announced | – | Biotech+2 | Stake in Anagram Therapeutics |
| May 2026 | Perfuse Therapeutics | – | Bayer | Acquisition | Legal adviser to Perfuse Therapeutics (target) | Announced | 300.0 | Biotech+2 | Bayer acquisition of Perfuse Therapeutics |
| May 2026 | LimmaTech Biologics AG | – | Eli Lilly and Company | Acquisition | Legal adviser to LimmaTech Biologics AG (target) | Pending | 780.0 | Biotech | Eli Lilly and Company acquisition of LimmaTech Biologics AG |
| Apr 2026 | Kelonia Therapeutics | – | Eli Lilly and Company | Acquisition | Legal adviser to Kelonia Therapeutics (target) | Announced | 7,000.0 | Biotech+2 | Eli Lilly and Company acquisition of Kelonia Therapeutics |
| Apr 2026 | Obsidian Therapeutics | – | – | Placement | Legal adviser to Obsidian Therapeutics | Completed | 350.0 | Biotech+2 | Obsidian Therapeutics placement |
| Apr 2026 | Obsidian Therapeutics | – | Galera Therapeutics | Merger | Legal adviser to Obsidian Therapeutics | Completed | 413.5 | Biotech+2 | Galera Therapeutics and Obsidian Therapeutics merger |
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Legal adviser to Tubulis (target) | Announced | 3,150.0 | Biotech+2 | Gilead Sciences acquisition of Tubulis |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Legal adviser to Ouro Medicines (target) | Announced | 1,675.0 | Biotech+1 | Gilead acquisition of Ouro Medicines |
| Mar 2026 | Pikavation | Synnovation | Novartis | Acquisition | Legal adviser to Synnovation Therapeutics (seller) | Announced | 2,000.0 | Biotech+2 | Novartis acquisition of Pikavation |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Legal adviser to Orna Therapeutics (target) | Announced | 2,400.0 | Biotech+1 | Eli Lilly and Company acquisition of Orna Therapeutics |
Deals where Arman Oruc is named on the firm's deal team, by the firm or the press.